Tag: Somatuline
In Memoriam: Edda Gomez-Panzani, MD
July 9, 2015
It is with deep sorrow that we learned of the passing of Edda Gomez-Panzani, MD on June 30, 2015. The NorCal CarciNET Community shared a tribute to Edda who “was instrumental in gaining FDA approval for Somatuline (lanreotide) for NETs patients …
READ MORE10 Highlights for the Carcinoid and Neuroendocrine Tumor Community
June 12, 2015
- PET/CT using Gallium-68 DOTATOC captures hidden source of neuroendocrine cancer. “An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society
10 Highlights of the Year 2014 for the Carcinoid and Neuroendocrine Tumor Community
December 18, 2014
As the Carcinoid Cancer Foundation looks back on the year 2014, we reached out to physicians, patients, support group leaders, listserv managers, patient advocates, and business colleagues to see what they thought were among the highlights of the past…
READ MORENow Recruiting: Carcinoid Syndrome Patients to Participate in Clinical Trial
June 17, 2011
Ipsen is recruiting patients with a history of carcinoid syndrome to participate in a clinical study to evaluate the effect of Somatuline® Depot (Lanreotide Autogel), a somatostatin analog (SSTa) similar to octreotide, on the control of symptoms …
READ MORE